secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2024-01-24T23:59:59+00:00
Accession:  0001100682-24-000004
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Labs appoints Reshema Kemps-Polanco to board; board expands to 12
-------------------------------------------------------------------------------

- Board increased from 11 to 12; Kemps-Polanco appointed effective Jan 22, 2024.
- She will serve on Compensation Committee and Strategic Planning and Capital Allocation Committee.
- Received initial pro-rata equity award valued at $255,500 in RSUs and stock options.
- Kemps-Polanco is EVP and Chief Commercial Officer of Novartis US with 25 years pharma experience.
- No material transactions or arrangements with Kemps-Polanco requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068224000004/0001100682-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068224000004/crl-20240122.htm
  HTML page:      https://secwatch.observer/filing/0001100682-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer